Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
How It Works 
News - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI Summary - About
Cellectis SA(CLLS)
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Stock price based on last close Advisory Performance History (Simulated)
Upturn Advisory & Investor View for CLLS
09/25/2026: CLLS (1-star) is currently NOT-A-BUY. Pass it for now.
Cellectis SA is a clinical-stage biotechnology company that focuses on developing innovative allogeneic, or 'off-the-shelf', CAR-T cell therapies to treat various cancers. The company's main strength lies in its proprietary TALEN gene-editing technology, which has enabled it to forge significant strategic partnerships. The primary growth story revolves around the successful clinical advancement of its allogeneic candidates and the potential for these products to solve scalability issues found in existing therapies. However, the company faces substantial execution, financial, and competitive risks, as it currently lacks commercial revenue and faces fierce competition in the oncology space. This stock is suitable only for high-risk, long-term biotech investors who monitor clinical trial outcomes closely.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
Company fundamentals, valuation, risks, and news provide supporting context about the business.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Mixed fit | The company offers high-growth potential linked to biotechnology innovation but carries extreme uncertainty. |
| Momentum investor | Mixed fit | This is a volatile stock where momentum is highly dependent on clinical trial results and partnership news. |
| Value investor | Weak fit | As a loss-making, clinical-stage company, it does not meet traditional value investing criteria. |
| Dividend investor | Weak fit | Cellectis does not pay dividends and focuses entirely on research and development. |
| Low-risk investor | Weak fit | The high volatility and risk of total loss inherent in biotechnology make this unsuitable for low-risk investors. |
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Price volatility | High | Clinical-stage biotech stocks are susceptible to massive price swings based on news cycles. |
| Valuation risk | High | Valuation is speculative as it depends on future success of unproven therapeutic candidates. |
| Competition risk (allogeneic cell therapy competition) | High | Numerous well-funded competitors are pursuing similar allogeneic CAR-T technologies. |
| Business quality | Medium | While the platform is scientifically respected, the business model currently lacks commercial product revenue. |
| Dividend income | Low / none | No income is generated for investors through dividends. |
| Execution risk | High | Success depends entirely on complex clinical development and regulatory approval pathways. |
Price Behavior
Steep Decline
The stock price has dropped sharply with strong downward pressure.
Extreme Price Shocks
The stock has experienced exceptionally large and disruptive price movements during the period.
Analysis of Past Performance
Type Stock | Historic Profit -21.42% | Avg. Invested days 30 | Today’s Advisory PASS |
Upturn Advisory Rating  | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 09/25/2026 |
Upturn Scorecard
Upturn Star Rating 
Company Fundamentals
Financial Health Rating
Growth Momentum Score
Ownership
Top 5 Institutional Investors
Unit Economics (Per $1K Revenue)
Economic Dimensions
Quantitative Style Profile
Style Classification
Quality Focused
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 144.03M USD | Price to earnings Ratio - | 1Y Target Price 5.33 |
Price to earnings Ratio - | 1Y Target Price 5.33 | ||
Volume (30-day avg) 135.9K shares | Beta 2.77 | 52 Weeks Range 1.25 - 5.48 | Updated Date 09/25/2026 |
52 Weeks Range 1.25 - 5.48 | Updated Date 09/25/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.63 |
How Company Makes Money
| Business area | What it includes | Retail investor read |
|---|---|---|
| Licensing and Collaboration | Payments from partners for the use of Cellectis's TALEN technology. | Revenue is unpredictable and driven by one-time payments from strategic deals. |
| Research and Development | Clinical trial milestones and potential future drug sales. | The company is currently burning cash to build a future portfolio of drug products. |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Valuation
Trailing PE - | Forward PE - | Enterprise Value 78.34M | Price to Sales(TTM) 2.26 |
Enterprise Value 78.34M | Price to Sales(TTM) 2.26 | ||
Enterprise Value to Revenue 1.38 | Enterprise Value to EBITDA -3.9 | Shares Outstanding 72.72M | Shares Floating 48.58M |
Shares Outstanding 72.72M | Shares Floating 48.58M | ||
Percent Insiders - | Percent Institutions 15.36 |
Upturn AI Summary
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
Financial Metrics
🧭 Investment Snapshot
Total Revenue (Scale)
Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.
Net Income (Profit)
Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.
Free Cash Flow (Cash Strength)
Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.
📈 Growth & Strength
Operating Income (Core Profit)
Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.
EBITDA (Cash Earnings)
Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.
Gross Profit (Unit Profitability)
Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.
🛡️ Financial Safety
Cash (Liquidity Buffer)
Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.
Total Debt (Leverage Risk)
Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.
Net Working Capital (Short-Term Health)
Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.
🧱 Balance Sheet Strength
Stockholder Equity (Net Worth)
Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.
Total Assets (Asset Base)
The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.
Income Before Tax (Pre-Tax Earnings)
Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.
⚙️ Cost & Drag Factors
Cost of Revenue (Production Cost)
Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.
Total Operating Expenses (Operating Cost)
Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.
Income Tax Expense (Tax Drag)
Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.
About Cellectis SA
Exchange NASDAQ | Headquarters - | ||
IPO Launch date 2007-02-07 | Co-Founder, CEO & Director Dr. Andre Choulika Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 224 | Website https://www.cellectis.com |
Full time employees 224 | Website https://www.cellectis.com | ||
Cellectis S.A., a clinical stage biotechnological company, develops products based on gene-editing with a portfolio of allogeneic chimeric antigen receptor T-cells product candidates in the field of immuno-oncology and gene therapy product candidates in other therapeutic indications. The company is developing BALLI-01, to evaluate the safety, expansion, persistence, and clinical activities of lasme-cel in patients with r/r ALL; NatHaLi-01, designed to evaluate the safety, expansion, persistence, and clinical activity of eti-cel in patients with relapsed or refractory B-Cell Non-Hodgkin's Lymphoma (B-NHL). It also develops ALPHA3, targets Large B-Cell Lymphoma (LBCL); TRAVERSE, for the treatment of patients with advanced or metastatic clear cell renal cell carcinoma (RCC). In addition, the company Melanoma, for treatment of unresectable or metastatic melanoma. Cellectis S.A. was founded in 1999 and is headquartered in Paris, France.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.